Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: predictable tool of relapse?

abstract：:Four novel 4-substituted 5-nitrophthalimides (5-substituted-6-nitro-1,3-dihydro-isoindol-1,3-diones), 6, 7, 10 and 11, and the known 5 are prepared as analogs of the dinitrobenzamide prodrug CB 1954, 1, and considered as potential candidates for gene-directed enzyme prodrug therapy. All the phthalimides are poor subst...

journal_title：Anti-cancer drugs

authors： Mehta LK,Hobbs S,Chen S,Knox RJ,Parrick J

更新日期：1999-09-01 00:00:00

abstract：:An international meeting on 'New Drugs in Cancer Therapy' was held at the National Tumor Institute of Naples, on 17-18 June 2004. The first session of the meeting focused on analogs of conventional anti-cancer drugs, such as taxanes, platinum compounds, anthracyclines and topoisomerase I inhibitors. The data of a phas...

journal_title：Anti-cancer drugs

authors： Caponigro F,Basile M,de Rosa V,Normanno N

更新日期：2005-02-01 00:00:00

abstract：:Paeonol, a major phenolic component of Moutan Cortex, is known to have antitumor effects through an unknown mechanism. In this study, we tried to elucidate the anticancer effects of paeonol on human hepatocellular carcinoma (HCC) cell lines BEL-7404, SMMC-7721, and MHCC97-H in vitro. Using the 3-[4,5-dimethylthiazol-2...

journal_title：Anti-cancer drugs

authors： Chunhu Z,Suiyu H,Meiqun C,Guilin X,Yunhui L

更新日期：2008-04-01 00:00:00

abstract：:Amifostine is a broad-spectrum cytoprotective agent approved for protection against cisplatin toxicities and radiation-induced xerostomia; strong clinical evidence exists that amifostine protects normal mucosa and lung from radiation damage. Hypotension, nausea/vomiting, fatigue and fever/rash are the main side-effect...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Maltezos E

更新日期：2006-02-01 00:00:00

abstract：:In an effort to develop new agents and molecular targets for the treatment of cancer, aspargine-glycine-arginine (NGR)-targeted liposomal doxorubicin (TVT-DOX) is being studied. The NGR peptide on the surface of liposomal doxorubicin (DOX) targets an aminopeptidase N (CD13) isoform, specific to the tumor neovasculatur...

journal_title：Anti-cancer drugs

authors： Garde SV,Forté AJ,Ge M,Lepekhin EA,Panchal CJ,Rabbani SA,Wu JJ

更新日期：2007-11-01 00:00:00

abstract：:Marine alkaloid meridianin G derivatives, substituted on the pyrimidine ring by aryl groups, were evaluated for their kinase inhibitory potencies and their in-vitro antiproliferative activities. The derivatives were tested toward a panel of nine protein kinases (KDR, IGF-1R, c-Met, RET, c-Src, c-Abl, PKA, CDK2/cyclin ...

journal_title：Anti-cancer drugs

authors： Rossignol E,Debiton E,Fabbro D,Moreau P,Prudhomme M,Anizon F

更新日期：2008-09-01 00:00:00

abstract：:Ecteinascidin 743 (Et743) is an interesting compound in phase II/III clinical trials. Its chemistry is complex, its mechanism of action is original and it is active in human cancers, such as sarcomas refractory to conventional chemotherapy. The present review describes the discovery of the drug, its specific interacti...

journal_title：Anti-cancer drugs

authors： Aune GJ,Furuta T,Pommier Y

更新日期：2002-07-01 00:00:00

abstract：:Metastatic meningioma is a rare disease, which has no effective chemotherapy. We report on a treatment of this condition with Doxil, a liposomal doxorubicin formulation. A 60-year-old woman with massive pleuro-pulmonary metastases from recurrent cranial meningioma was treated with Doxil (50-37.5 mg/m2) for 18 months w...

journal_title：Anti-cancer drugs

authors： Travitzky M,Libson E,Nemirovsky I,Hadas I,Gabizon A

更新日期：2003-03-01 00:00:00

abstract：:Mitoxantrone is a DNA topoisomerase II poison commonly used for the treatment of hormone-refractory prostate cancer. The risk of secondary leukaemia is well described after mitoxantrone treatment in breast cancer and multiple sclerosis. Recent improvements of systemic chemotherapy increased the median survival in pati...

journal_title：Anti-cancer drugs

authors： Martinez V,Mir O,Dômont J,Bouscary D,Goldwasser F

更新日期：2007-02-01 00:00:00

abstract：:Panitumumab has proven efficacy in patients with metastatic or locally advanced colorectal cancer patients, provided that they have no activating KRAS mutation in their tumour. Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification of KRAS. We hypothesize that the act...

journal_title：Anti-cancer drugs

authors： Baas JM,Krens LL,Bos MM,Portielje JE,Batman E,van Wezel T,Morreau H,Guchelaar HJ,Gelderblom H

更新日期：2015-09-01 00:00:00

abstract：:We have previously shown that L-methionine inhibits proliferation of breast, prostate, and colon cancer cells. This study extends these findings to BXPC-3 (mutated p53) and HPAC (wild-type p53) pancreatic cancer cells and explores the reversibility of these effects. Cells were exposed to L-methionine (5 mg/ml) for 7 d...

journal_title：Anti-cancer drugs

authors： Benavides MA,Bosland MC,da Silva CP,Gomes Sares CT,de Oliveira AM,Kemp R,dos Reis RB,Martins VR,Sampaio SV,Bland KI,Grizzle WE,dos Santos JS

更新日期：2014-02-01 00:00:00

abstract：:The goal of this study was to identify clinical characteristics and concurrent medications associated with an increased or decreased incidence of cisplatin-induced nephrotoxicity. The medical records for 62 subjects with head and neck cancer who received cisplatin 100 mg/m2 (day 1) plus fluorouracil 1000 mg/m2 (days 1...

journal_title：Anti-cancer drugs

authors： Shord SS,Thompson DM,Krempl GA,Hanigan MH

更新日期：2006-02-01 00:00:00

abstract：:Monoclonal antibodies such as rituximab and alemtuzumab show considerable therapeutic efficacy in chronic lymphocytic leukaemia (CLL). Aiming to further improve antineoplastic efficacy, the trifunctional bispecific antibody FBTA05 was developed. FBTA05 is thought to function by simultaneously binding B cells and T cel...

journal_title：Anti-cancer drugs

authors： Boehrer S,Schroeder P,Mueller T,Atz J,Chow KU

更新日期：2011-07-01 00:00:00

abstract：:We present the case of a 70-year-old patient affected by metastatic castration-resistant prostate cancer. He underwent radical prostatectomy in 2007 and subsequent adjuvant radiotherapy and hormonal therapy for 2 years. In 2011, he developed bilateral lung metastases, and therefore he received chemotherapy (eight cycl...

journal_title：Anti-cancer drugs

authors： Bolzacchini E,Patriarca C,Giordano M

更新日期：2021-01-01 00:00:00

abstract：:Multidrug resistance (MDR) is a major obstacle to successful chemotherapy for cancer; thus, novel MDR reversers are urgently needed. In the present study, we assessed whether two synthetic derivatives of 23-hydroxybetulinic acid, 3,23-O-diacetyl-17-1,4'-bipiperidinyl betulinic amide (DABB) and 3,23-O-dihydroxy-17-1,4'...

journal_title：Anti-cancer drugs

authors： Zhang DM,Li YJ,Shu C,Ruan ZX,Chen WM,Yiu A,Peng YH,Wang J,Lan P,Yao Z,Fung KP,Fu LW,Chen ZS,Ye WC

更新日期：2013-06-01 00:00:00

abstract：:Esophageal cancer is one of the fatal cancers around the world. Dexmedetomidine (DEX) is widely used during anesthesia of esophageal cancer surgery. Nevertheless, the role of DEX in the progression of esophageal cancer remains barely known. The proliferation, apoptosis and metastasis of esophageal cancer cells were de...

journal_title：Anti-cancer drugs

authors： Zhang P,He H,Bai Y,Liu W,Huang L

更新日期：2020-08-01 00:00:00

abstract：:Gossypol [(2,2'-binaphthalene)-8,8'-dicarboxaldehyde-1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl] 1a is a naturally occurring compound extracted from the cotton plant and has been extensively studied as an oral male contraceptive. Its favorable toxicity profile, and the more recent demonstration of anti-...

journal_title：Anti-cancer drugs

authors： Shelley MD,Hartley L,Groundwater PW,Fish RG

更新日期：2000-03-01 00:00:00

abstract：:In a retrospective study, we calculated the treatment and follow-up costs of patients with newly diagnosed multiple myeloma. The total treatment programme consisted of eight phases: VAD or VAMP chemotherapy, follow-up I, high-dose melphalan followed by transplantation of whole blood, follow-up II, collection of periph...

journal_title：Anti-cancer drugs

authors： Buijt I,Ossenkoppele GJ,Uyl-de Groot CA,Huijgens PC

更新日期：1998-11-01 00:00:00

abstract：:OncoGel is a novel depot formulation of paclitaxel designed for intralesional injection with a sustained paclitaxel delivery over approximately 6 weeks from a single administration. This phase 1 study was designed to characterize the toxicity, pharmacokinetics and preliminary antitumor activity associated with OncoGel...

journal_title：Anti-cancer drugs

authors： Vukelja SJ,Anthony SP,Arseneau JC,Berman BS,Cunningham CC,Nemunaitis JJ,Samlowski WE,Fowers KD

更新日期：2007-03-01 00:00:00

abstract：:Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2 every 3 weeks, over 3 h infusion. Thirty-six patients entered the study, and all of them were evaluable for response and toxi...

journal_title：Anti-cancer drugs

authors： Cascinu S,Graziano F,Cardarelli N,Marcellini M,Giordani P,Menichetti ET,Catalano G

更新日期：1998-04-01 00:00:00

abstract：:At the present time, there is not a standard regimen in upfront metastatic setting for breast cancer. A wide variety of regimens which includes anthracyclines, taxanes, gemcitabine or capecitabine are currently used, however, there is evidence to support the use of many of these drugs in early breast cancer and conseq...

journal_title：Anti-cancer drugs

authors： Estevez LG,Tusquets I,Muñoz M,Adrover E,Rovira PS,Seguí MA,Rodríguez CA,Lescure AR,Ruiz M,Alvarez I,Mata JG

更新日期：2007-08-01 00:00:00

abstract：:The results of several preclinical and clinical studies were reported by oncology professionals at the 43rd American Society of Clinical Oncology (ASCO) meeting, the largest international forum in which the latest achievements in cancer research are annually presented. The central theme this year was 'Translating Rese...

journal_title：Anti-cancer drugs

authors： Puglisi F,Aprile G,Fasola G

更新日期：2008-02-01 00:00:00

abstract：:This study examined the growth inhibitory effects of combining 1,25-dihydroxyvitamin D3 (calcitriol) with retinoic acid or dexamethasone against cultured breast and ovarian carcinoma cells. Retinoic acid (12.5-50 nM) increased the effectiveness of calcitriol (12.5-50 nM) against MCF-7 and NIH:OVCAR3 cells, with synerg...

journal_title：Anti-cancer drugs

authors： Saunders DE,Christensen C,Williams JR,Wappler NL,Lawrence WD,Malone JM,Malviya VK,Deppe G

更新日期：1995-08-01 00:00:00

abstract：:Isoquercitrin isolated from the aerial parts of Hyptis fasciculata was evaluated according to its capacity to interfere with glioblastoma (Gbm) cell growth. Gbm cells were incubated with isoquercitrin, quercetin, or rutin at concentrations of 25, 50, and 100 mumol/l for 24, 48, and 72 h. Quercetin and rutin affected G...

journal_title：Anti-cancer drugs

authors： Amado NG,Cerqueira DM,Menezes FS,da Silva JF,Neto VM,Abreu JG

更新日期：2009-08-01 00:00:00

abstract：:The efficacy of trastuzumab beyond metastatic disease progression (PD) is controversial. We retrospectively analyzed 213 patients with HER2-positive metastatic breast cancer treated with trastuzumab-based therapies between November 1998 and December 2010. Out of 213 patients, 134 (58%) had received trastuzumab consecu...

journal_title：Anti-cancer drugs

authors： Esposito A,Munzone E,Bagnardi V,Adamoli L,Sciandivasci A,Cullurà D,Goldhirsch A,Nolè F

更新日期：2012-11-01 00:00:00

abstract：:There is growing interest in the discovery of bioactive metabolites from endophytes as an alternative source of therapeutics. Identification of their therapeutic targets is essential in understanding the underlying mechanisms and enhancing the resultant therapeutic effects. As such, bioactive compounds produced by end...

journal_title：Anti-cancer drugs

authors： Hazalin NA,Lim SM,Cole AL,Majeed AB,Ramasamy K

更新日期：2013-09-01 00:00:00

abstract：:The primary aim of this randomized trial was to determine response rate and progression-free survival following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an ATP-based tumour chemosensitivity assay in comparison with physician's choice. A total of 180 p...

journal_title：Anti-cancer drugs

authors： Cree IA,Kurbacher CM,Lamont A,Hindley AC,Love S,TCA Ovarian Cancer Trial Group.

更新日期：2007-10-01 00:00:00

abstract：:Uterine sarcomas are rare tumors constituting 1-3% of all uterine malignancies. These tumors are characterized by aggressive growth and by poor overall prognosis. There is much controversy concerning diagnostic criteria and the great variation in histology, as well as the role of radiotherapy and chemotherapy in the m...

journal_title：Anti-cancer drugs

authors： Meden H,Meyer-Rath D,Schauer A,Kuhn W

更新日期：1991-02-01 00:00:00

abstract：:Colorectal cancer occurs throughout the world but is most common in developed countries. Cancer progression is believed to be driven by genetic mutations in this complex condition. Risk factors for developing colorectal cancer include a genetic family history, long-term ulcerative colitis, and colonic polyps. The use ...

journal_title：Anti-cancer drugs

authors： Ma W,Liu X,Du W

更新日期：2019-02-01 00:00:00

abstract：:Lung cancer always ranks first in the number of cancer deaths every year, accounting for 18.4% of total cancer deaths in 2018. Metastasis is the main cause of death in lung cancer patients. The identification of bioactive components of traditional Chinese medicine is very important for the development of novel reagent...

journal_title：Anti-cancer drugs

authors： Ni L,Li Z,Shi X,Yao C,Sun J,Ai M,Li S,Liu Y,Xu F,Zhou Y,Li J,Qiu L

更新日期：2020-11-01 00:00:00